{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:13:13Z","timestamp":1791922393396,"version":"4.3.4"},"reference-count":185,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020703","name":"Department of Pharmaceutical Sciences, St. John's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010937","name":"St. John's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bbcan.2025.189461","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:24:50Z","timestamp":1759209890000},"page":"189461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies"],"prefix":"10.1016","volume":"1880","author":[{"given":"Deepika","family":"Godugu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameswari","family":"Chilamakuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2025.189461_bb0005","series-title":"Methods in Enzymology [Internet]","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0076-6879(01)33052-5","article-title":"STAT proteins: signal tranducers and activators of transcription","author":"Bromberg","year":"2001"},{"key":"10.1016\/j.bbcan.2025.189461_bb0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2022.11.011","article-title":"The STAT family: key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment","volume":"88","author":"Zhu","year":"2023","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0015","first-page":"1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal. Transduct. Target Ther."},{"key":"10.1016\/j.bbcan.2025.189461_bb0020","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3389\/fimmu.2019.02056","article-title":"STAT3 mediates the differential effects of oncostatin M and TNF\u03b1 on RA synovial fibroblast and endothelial cell function","volume":"10","author":"Hanlon","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in Cancer Immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12964-020-00627-5","article-title":"Drug resistance and Cancer stem cells","volume":"19","author":"Li","year":"2021","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct Target Ther."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189461_bb0040","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189461_bb0045","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","article-title":"FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling","volume":"76","author":"Yang","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nm976","article-title":"Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells","volume":"10","author":"Wang","year":"2004","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189461_bb0055","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210759","article-title":"A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance","volume":"218","author":"Warshauer","year":"2021","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189461_bb0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3892\/ijo.2024.5636","article-title":"Role of STAT3 in cancer cell epithelial-mesenchymal transition (Review)","volume":"64","author":"Zhang","year":"2024","journal-title":"Int. J. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189461_bb0075","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.3390\/pharmaceutics14122787","article-title":"Nanoparticle-mediated delivery of STAT3 inhibitors in the treatment of lung cancer","volume":"14","author":"Feng","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189461_bb0065","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3390\/cancers11111681","article-title":"Targeting STAT3 in cancer with nucleotide therapeutics","volume":"11","author":"Lau","year":"2019","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189461_bb0070","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.ymthe.2024.03.035","article-title":"RNAi mediated silencing of STAT3\/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors","volume":"32","author":"Ganesh","year":"2024","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189461_bb0085","article-title":"STAT3 pathway in cancers: past, present, and future","volume":"3","author":"Wang","year":"2022","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.bbcan.2025.189461_bb0090","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13045-021-01214-y","article-title":"STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer","volume":"14","author":"Awasthi","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189461_bb0100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.biocel.2019.02.006","article-title":"STAT3beta, a distinct isoform from STAT3","volume":"110","author":"Zhang","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189461_bb0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cyto.2018.07.014","article-title":"STAT3 isoforms: alternative fates in cancer?","volume":"118","author":"Aigner","year":"2019","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189461_bb0110","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/cells10071610","article-title":"Targeting canonical and non-canonical STAT signaling pathways in renal diseases","volume":"10","author":"Gai","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease","volume":"194","author":"Villarino","year":"2015","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189461_bb0120","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/JCO.2010.31.8907","article-title":"Targeting the interleukin-6\/Jak\/Stat pathway in human malignancies","volume":"30","author":"Sansone","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2025.189461_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08977194.2018.1473393","article-title":"STAT3: a multifaceted oncoprotein","volume":"36","author":"Guanizo","year":"2018","journal-title":"Growth Factors"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189461_bb0125","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.neo.2021.10.003","article-title":"STAT3 as a mediator of oncogenic cellular metabolism: pathogenic and therapeutic implications","volume":"23","author":"To\u0161i\u0107","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2025.189461_bb0130","doi-asserted-by":"crossref","first-page":"17663","DOI":"10.1038\/srep17663","article-title":"Multiple regulation pathways and pivotal biological functions of STAT3 in cancer","volume":"5","author":"Yuan","year":"2015","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189461_bb0135","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006098","article-title":"Signal transduction in cancer","volume":"5","author":"Sever","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bbcan.2025.189461_bb0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2017.12.003","article-title":"The role of STAT3 in leading the crosstalk between human cancers and the immune system","volume":"415","author":"Wang","year":"2018","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189461_bb0145","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.4049\/jimmunol.1401779","article-title":"Non-canonical STAT3 activation regulates excess TGF-\u03b21 and Collagen I expression in muscle of stricturing Crohn\u2019s disease","volume":"194","author":"Li","year":"2015","journal-title":"J. Immunol."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189461_bb0155","doi-asserted-by":"crossref","first-page":"14192","DOI":"10.1074\/jbc.M111.323899","article-title":"Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA","volume":"287","author":"Timofeeva","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"183","key":"10.1016\/j.bbcan.2025.189461_bb0160","doi-asserted-by":"crossref","first-page":"721","DOI":"10.24976\/Discov.Med.202436183.68","article-title":"EZH2 promotes multiple myeloma progression via STAT3 pathway activation","volume":"36","author":"Wang","year":"2024","journal-title":"Discov. Med."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189461_bb0165","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41419-023-06148-6","article-title":"PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Cell Death Dis."},{"issue":"50","key":"10.1016\/j.bbcan.2025.189461_bb0170","doi-asserted-by":"crossref","first-page":"21499","DOI":"10.1073\/pnas.1016147107","article-title":"Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189461_bb0175","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3390\/ijms19092708","article-title":"Protein tyrosine phosphatases as potential regulators of STAT3 signaling","volume":"19","author":"Kim","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.bbcan.2025.189461_bb0180","doi-asserted-by":"crossref","first-page":"8150","DOI":"10.1073\/pnas.0501643102","article-title":"STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-\u03b13","volume":"102","author":"Liu","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"30","key":"10.1016\/j.bbcan.2025.189461_bb0185","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000043476","article-title":"Advances in research on unphosphorylated STAT3: a review","volume":"104","author":"Zhang","year":"2025","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189461_bb0190","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.prp.2016.03.001","article-title":"Nuclear unphosphorylated STAT3 correlates with a worse prognosis in human glioblastoma","volume":"212","author":"Rodrigues","year":"2016","journal-title":"Pathol. Res. Pract."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189461_bb0195","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7150\/ijbs.8193","article-title":"SRC-1 and Twist1 expression positively correlates with a poor prognosis in human breast cancer","volume":"10","author":"Xu","year":"2014","journal-title":"Int. J. Biol. Sci."},{"issue":"37","key":"10.1016\/j.bbcan.2025.189461_bb0205","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103444118","article-title":"IL-6 enhances CD4 cell motility by sustaining mitochondrial Ca2+ through the noncanonical STAT3 pathway","volume":"118","author":"Valen\u00e7a-Pereira","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0210","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12964-023-01421-9","article-title":"The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors","volume":"22","author":"Zhao","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.bbcan.2025.189461_bb0215","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cyto.2016.06.017","article-title":"JAK-STAT signaling in cancer: from cytokines to non-coding genome","volume":"87","author":"Pencik","year":"2016","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0220","doi-asserted-by":"crossref","first-page":"19552","DOI":"10.1038\/s41598-023-46628-5","article-title":"STAT3 phosphorylation at serine 727 activates specific genetic programs and promotes clear cell renal cell carcinoma (ccRCC) aggressiveness","volume":"13","author":"Ar\u00e9valo","year":"2023","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189461_bb0225","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5483\/BMBRep.2019.52.7.152","article-title":"Highlighted STAT3 as a potential drug target for cancer therapy","volume":"52","author":"Lee","year":"2019","journal-title":"BMB Rep."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189461_bb0230","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492835","article-title":"Frequent mutations in natural killer\/T cell lymphoma","volume":"49","author":"Zhang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189461_bb0240","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.3390\/cancers11111646","article-title":"STAT3: an emerging therapeutic target for hepatocellular carcinoma","volume":"11","author":"Lee","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189461_bb0245","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189461_bb0250","doi-asserted-by":"crossref","first-page":"116010","DOI":"10.1016\/j.celrep.2025.116010","article-title":"A STAT3\/integrin axis accelerates pancreatic cancer initiation and progression","volume":"44","author":"Campos","year":"2025","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189461_bb0255","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1074-7613(00)80501-4","article-title":"Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis","volume":"5","author":"Fukada","year":"1996","journal-title":"Immunity"},{"issue":"Pt 2","key":"10.1016\/j.bbcan.2025.189461_bb0260","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/BJ20050465","article-title":"STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells","volume":"392","author":"Bhattacharya","year":"2005","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189461_bb0265","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/ijms22020603","article-title":"The multifaced role of STAT3 in cancer and its implication for anticancer therapy","volume":"22","author":"Tolomeo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189461_bb0270","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.7150\/jca.38798","article-title":"Activated STAT3 could reduce survival in patients with esophageal squamous cell carcinoma by up-regulating VEGF and cyclin D1 expression","volume":"11","author":"Zhang","year":"2020","journal-title":"J. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189461_bb0275","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3390\/cancers14071785","article-title":"Cell type-specific roles of STAT3 signaling in the pathogenesis and progression of K-ras mutant lung adenocarcinoma","volume":"14","author":"Clowers","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.bbcan.2025.189461_bb0280","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1038\/sj.onc.1208469","article-title":"Stat3 regulates genes common to both wound healing and cancer","volume":"24","author":"Dauer","year":"2005","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189461_bb0285","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1346-8138.2005.tb00906.x","article-title":"Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma","volume":"32","author":"Suiqing","year":"2005","journal-title":"J. Dermatol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189461_bb0290","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.3390\/cancers14071847","article-title":"MMP9: a tough target for targeted therapy for cancer","volume":"14","author":"Augoff","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189461_bb0295","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.cellsig.2009.01.034","article-title":"EGF-induced MMP-9 expression is mediated by the JAK3\/ERK pathway, but not by the JAK3\/STAT-3 pathway in a SKBR3 breast cancer cell line","volume":"21","author":"Kim","year":"2009","journal-title":"Cell. Signal."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189461_bb0300","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3892\/or.2015.3783","article-title":"STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells","volume":"33","author":"Zhang","year":"2015","journal-title":"Oncol. Rep."},{"issue":"40","key":"10.1016\/j.bbcan.2025.189461_bb0305","doi-asserted-by":"crossref","first-page":"69139","DOI":"10.18632\/oncotarget.19932","article-title":"The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis","volume":"8","author":"Gao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189461_bb0310","author":"Seward"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189461_bb0315","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1172\/JCI35213","article-title":"Stat3 mediates myeloid cell\u2013dependent tumor angiogenesis in mice","volume":"118","author":"Kujawski","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189461_bb0320","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.onc.1206122","article-title":"Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis","volume":"22","author":"Wei","year":"2003","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189461_bb0325","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3390\/biomedicines9081016","article-title":"Targeting STAT3 signaling pathway in colorectal cancer","volume":"9","author":"Gargalionis","year":"2021","journal-title":"Biomedicines"},{"issue":"24","key":"10.1016\/j.bbcan.2025.189461_bb0330","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.3390\/cancers13246228","article-title":"Multicellular effects of STAT3 in non-small cell lung cancer: mechanistic insights and therapeutic opportunities","volume":"13","author":"Parakh","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189461_bb0335","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41420-023-01507-w","article-title":"STAT3 and HIF1\u03b1 cooperatively mediate the transcriptional and physiological responses to hypoxia","volume":"9","author":"Dinarello","year":"2023","journal-title":"Cell Death Dis."},{"issue":"36","key":"10.1016\/j.bbcan.2025.189461_bb0340","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1038\/sj.onc.1208719","article-title":"Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways","volume":"24","author":"Xu","year":"2005","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189461_bb0345","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/2211-5463.13270","article-title":"ZIPK activates the IL-6\/STAT3 signaling pathway and promotes cisplatin resistance in gastric cancer cells","volume":"11","author":"Fan","year":"2021","journal-title":"FEBS Open Bio."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189461_bb0350","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.18632\/aging.203301","article-title":"The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation","volume":"13","author":"Guo","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bbcan.2025.189461_bb0355","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2019.11.017","article-title":"JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK\/STAT signalling pathway in ovarian cancer","volume":"126","author":"Bagratuni","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0360","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13046-022-02376-4","article-title":"Interleukin-6 mediated inflammasome activation promotes oral squamous cell carcinoma progression via JAK2\/STAT3\/Sox4\/NLRP3 signaling pathway","volume":"41","author":"Xiao","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189461_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.536","article-title":"Selenium sulfide disrupts the PLAGL2\/C-MET\/STAT3-induced resistance against mitochondrial apoptosis in hepatocellular carcinoma","volume":"11","author":"Yang","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189461_bb0370","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cytogfr.2025.01.003","article-title":"Insights into IL-6\/JAK\/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy","volume":"85","author":"Thuya","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189461_bb0375","doi-asserted-by":"crossref","first-page":"e70152","DOI":"10.1002\/mco2.70152","article-title":"STAT3 signaling pathway in health and disease","volume":"6","author":"Samad","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.bbcan.2025.189461_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115513","article-title":"Targeting the STAT3 oncogenic pathway: cancer immunotherapy and drug repurposing","volume":"167","author":"Dong","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189461_bb0385","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41385-019-0194-9","article-title":"IL-10 signaling in dendritic cells controls IL-1\u03b2-mediated IFN\u03b3 secretion by human CD4+ T cells: relevance to inflammatory bowel disease","volume":"12","author":"Veenbergen","year":"2019","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.bbcan.2025.189461_bb0390","doi-asserted-by":"crossref","first-page":"1160719","DOI":"10.3389\/fimmu.2023.1160719","article-title":"Advances in the role of STAT3 in macrophage polarization","volume":"14","author":"Xia","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189461_bb0395","doi-asserted-by":"crossref","first-page":"69","DOI":"10.25259\/Cytojournal_165_2024","article-title":"Association of immunosuppressive CD45+CD33+CD14- CD10-HLA-DR-\/low neutrophils with poor prognosis in patients with lymphoma and their expansion and activation through STAT3\/arginase-1 pathway in vitro","volume":"21","author":"Xiao","year":"2024","journal-title":"Cytojournal"},{"key":"10.1016\/j.bbcan.2025.189461_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.767939","article-title":"Exploiting the STAT3 nexus in cancer-associated fibroblasts to improve cancer therapy","volume":"12","author":"Allam","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189461_bb0405","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3390\/cancers15092536","article-title":"Significance of cancer-associated fibroblasts in the interactions of cancer cells with the tumor microenvironment of heterogeneous tumor tissue","volume":"15","author":"Arima","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0410","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13046-020-01709-5","article-title":"The role of microenvironment in tumor angiogenesis","volume":"39","author":"Jiang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0415","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1038\/s41598-017-02907-6","article-title":"VEGF-a stimulates STAT3 activity via nitrosylation of myocardin to regulate the expression of vascular smooth muscle cell differentiation markers","volume":"7","author":"Liao","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0425","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1172\/JCI41004","article-title":"The therapeutic promise of the cancer stem cell concept","volume":"120","author":"Frank","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189461_bb0430","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.biocel.2012.08.022","article-title":"Cancer stem cells","volume":"44","author":"Yu","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189461_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.909251","article-title":"STAT3 and p63 in the regulation of cancer stemness","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbcan.2025.189461_bb0440","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/708036","article-title":"Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity","volume":"2012","author":"Jaggupilli","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.bbcan.2025.189461_bb0445","doi-asserted-by":"crossref","first-page":"61","DOI":"10.25259\/Cytojournal_69_2024","article-title":"Preliminary study on the cellular and molecular mechanisms of Cms1 ribosomal small subunit homolog promoting hepatocellular carcinoma progression via activation of the homolog family member A\/yes-associated protein 1 signaling pathway","volume":"21","author":"Zheng","year":"2024","journal-title":"Cytojournal"},{"issue":"19","key":"10.1016\/j.bbcan.2025.189461_bb0450","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/onc.2016.418","article-title":"The LIM protein AJUBA promotes colorectal cancer cell survival through suppression of JAK1\/STAT1\/IFIT2 network","volume":"36","author":"Jia","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189461_bb0455","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211038492","article-title":"NANOG promotes cell proliferation, invasion, and stemness via IL-6\/STAT3 signaling in esophageal squamous carcinoma","volume":"20","author":"Deng","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.bbcan.2025.189461_bb0460","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13578-023-01118-z","article-title":"Post-translational modification of CDK1\u2013STAT3 signaling by fisetin suppresses pancreatic cancer stem cell properties","volume":"13","author":"Xu","year":"2023","journal-title":"Cell Biosci."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189461_bb0465","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1158\/0008-5472.CAN-14-2946","article-title":"G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent cancer stem cell activation","volume":"75","author":"Agarwal","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189461_bb0470","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/ph16010037","article-title":"Afatinib reverses EMT via inhibiting CD44-Stat3 axis to promote radiosensitivity in nasopharyngeal carcinoma","volume":"16","author":"Huang","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189461_bb0475","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2018.05.003","article-title":"Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling","volume":"33","author":"Dhar","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189461_bb0480","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.biomaterials.2016.07.040","article-title":"Isoproterenol regulates CD44 expression in gastric cancer cells through STAT3\/MicroRNA373 cascade","volume":"105","author":"Wei","year":"2016","journal-title":"Biomaterials"},{"issue":"3\u20134","key":"10.1016\/j.bbcan.2025.189461_bb0485","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1101\/gad.319889.118","article-title":"CD44 splice isoform switching determines breast cancer stem cell state","volume":"33","author":"Zhang","year":"2019","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189461_bb0490","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-11-0801","article-title":"STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression","volume":"11","author":"Kohsaka","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189461_bb0500","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/cancers17050755","article-title":"Targeting STAT3 for cancer therapy: focusing on Y705, S727, or dual inhibition?","volume":"17","author":"Berkley","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189461_bb0505","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fmolb.2020.00079","article-title":"Cancer stem cell plasticity \u2013 a deadly deal","volume":"7","author":"Thankamony","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189461_bb0510","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.semcancer.2012.02.013","article-title":"EMT as the ultimate survival mechanism of cancer cells","volume":"22","author":"Tiwari","year":"2012","journal-title":"Semin. Cancer Biol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189461_bb0515","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/15680096113136660102","article-title":"The role of snail in EMT and tumorigenesis","volume":"13","author":"Wang","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189461_bb0520","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/1541-7786.MCR-11-0371","article-title":"Temporal and Spatial cooperation of Snail1 and Twist1 during Epithelial-Mesenchymal Transition predicts for human breast cancer recurrence","volume":"9","author":"Tran","year":"2011","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0525","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cells9010217","article-title":"Role of JAK\/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial\u2013mesenchymal transition","volume":"9","author":"Jin","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189461_bb0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027720","article-title":"LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling","volume":"6","author":"Lue","year":"2011","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.bbcan.2025.189461_bb0535","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","article-title":"Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189461_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106311","article-title":"STAT3-EMT axis in tumors: modulation of cancer metastasis, stemness and therapy response","volume":"182","author":"Sadrkhanloo","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0545","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.canlet.2016.03.034","article-title":"Ovarian cancer stem-like cells differentiate into endothelial cells and participate in tumor angiogenesis through autocrine CCL5 signaling","volume":"376","author":"Tang","year":"2016","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189461_bb0550","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/onc.2017.404","article-title":"Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia","volume":"37","author":"Almiron Bonnin","year":"2018","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189461_bb0555","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41419-017-0176-3","article-title":"Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6\/JAK2\/STAT3 signaling","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189461_bb0560","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cellsig.2013.01.007","article-title":"Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells","volume":"25","author":"Kim","year":"2013","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189461_bb0565","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/cancers16030492","article-title":"Exploring novel frontiers: leveraging STAT3 signaling for advanced cancer therapeutics","volume":"16","author":"Adesoye","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0570","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41419-025-07535-x","article-title":"Decoy-PROTAC for specific degradation of \u201cUndruggable\u201d STAT3 transcription factor","volume":"16","author":"Li","year":"2025","journal-title":"Cell Death Dis."},{"issue":"23","key":"10.1016\/j.bbcan.2025.189461_bb0575","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.3390\/cancers15235647","article-title":"Oligonucleotide-based therapeutics for STAT3 targeting in cancer\u2014drug carriers matter","volume":"15","author":"Molenda","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2025.189461_bb0580","doi-asserted-by":"crossref","first-page":"1304342","DOI":"10.3389\/fphar.2023.1304342","article-title":"Antisense oligonucleotides: a novel Frontier in pharmacological strategy","volume":"14","author":"Collotta","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0585","doi-asserted-by":"crossref","first-page":"15316","DOI":"10.1038\/s41598-020-72136-x","article-title":"Beneficial effect of STAT3 decoy oligodeoxynucleotide transfection on organ injury and mortality in mice with cecal ligation and puncture-induced sepsis","volume":"10","author":"Imbaby","year":"2020","journal-title":"Sci. Rep."},{"issue":"314","key":"10.1016\/j.bbcan.2025.189461_bb0590","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189461_bb0595","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/2159-8290.CD-12-0191","article-title":"First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy","volume":"2","author":"Sen","year":"2012","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189461_bb0600","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ymthe.2018.02.006","article-title":"Decoy-based, targeted inhibition of STAT3: a new step forward for B cell lymphoma immunotherapy","volume":"26","author":"Soldevilla","year":"2018","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0605","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1038\/s41467-025-58921-0","article-title":"TRAPT: a multi-stage fused deep learning framework for predicting transcriptional regulators based on large-scale epigenomic data","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189461_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105637","article-title":"Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility","volume":"169","author":"Kong","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0615","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2013.02.010","article-title":"OPB-31121, a novel small molecular inhibitor, disrupts the JAK2\/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells","volume":"335","author":"Kim","year":"2013","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189461_bb0620","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4143\/crt.2014.249","article-title":"Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors","volume":"47","author":"Oh","year":"2015","journal-title":"Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189461_bb0625","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1634\/theoncologist.2017-0325","article-title":"A first-in-human phase I study of OPB-111077, a small-molecule STAT3 and oxidative phosphorylation inhibitor, in patients with advanced cancers","volume":"23","author":"Tolcher","year":"2018","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0630","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-017-2057-0","article-title":"The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer","volume":"67","author":"Khan","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189461_bb0635","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/pr.119.018440","article-title":"Targeting janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: Rationale, progress, and caution","volume":"72","author":"Bharadwaj","year":"2020","journal-title":"Pharmacol. Rev."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189461_bb0640","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1021\/jm101330h","article-title":"Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3)","volume":"54","author":"Li","year":"2011","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0660","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13046-019-1289-6","article-title":"Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells","volume":"38","author":"Han","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189461_bb0665","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.597520","article-title":"Napabucasin reduces cancer stem cell characteristics in hepatocellular carcinoma","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189461_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.708325","article-title":"Signal transducer and activator of transcription-3 modulation of cardiac pathology in chronic chagasic cardiomyopathy","volume":"11","author":"Hoffman","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0675","doi-asserted-by":"crossref","first-page":"F84","DOI":"10.1152\/ajprenal.00603.2019","article-title":"Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease","volume":"319","author":"Zhang","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189461_bb0680","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-18-3274","article-title":"Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer","volume":"25","author":"Kettner","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.bbcan.2025.189461_bb0685","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1182\/blood-2010-04-280123","article-title":"Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor","volume":"117","author":"Redell","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189461_bb0690","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/CAD.0000000000000783","article-title":"C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma","volume":"30","author":"Di","year":"2019","journal-title":"Anti-Cancer Drugs"},{"issue":"18","key":"10.1016\/j.bbcan.2025.189461_bb0695","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-16-2253","article-title":"Multi-functional effects of a small-molecule STAT3 inhibitor on NASH and HCC in mice","volume":"23","author":"Jung","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189461_bb0700","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.1533.3.12","article-title":"Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity","volume":"3","author":"Turkson","year":"2004","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0705","first-page":"44","article-title":"A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells","volume":"1","author":"Borghouts","year":"2012","journal-title":"JAKSTAT"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189461_bb0710","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.3390\/cancers14092297","article-title":"Atovaquone: an inhibitor of oxidative phosphorylation as studied in gynecologic cancers","volume":"14","author":"Kapur","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189461_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.836724","article-title":"Novel STAT3 inhibitors targeting STAT3 dimerization by binding to the STAT3 SH2 domain","volume":"13","author":"Hua","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"48","key":"10.1016\/j.bbcan.2025.189461_bb0720","doi-asserted-by":"crossref","first-page":"45443","DOI":"10.1074\/jbc.M107527200","article-title":"Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation","volume":"276","author":"Turkson","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189461_bb0725","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1535-7163.261.3.3","article-title":"Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity","volume":"3","author":"Turkson","year":"2004","journal-title":"Mol. Cancer Ther."},{"issue":"39","key":"10.1016\/j.bbcan.2025.189461_bb0730","doi-asserted-by":"crossref","first-page":"37610","DOI":"10.1074\/jbc.M301629200","article-title":"Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells","volume":"278","author":"Buerger","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189461_bb0735","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/147323001204000207","article-title":"Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma","volume":"40","author":"Ge","year":"2012","journal-title":"J. Int. Med. Res."},{"issue":"23","key":"10.1016\/j.bbcan.2025.189461_bb0740","doi-asserted-by":"crossref","first-page":"11291","DOI":"10.1158\/0008-5472.CAN-07-0593","article-title":"WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells","volume":"67","author":"Ferrajoli","year":"2007","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189461_bb0745","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/leu.2010.289","article-title":"The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival","volume":"25","author":"Scuto","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0755","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","article-title":"Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies","volume":"9","author":"Verstovsek","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189461_bb0760","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/leu.2011.148","article-title":"SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies","volume":"25","author":"Hart","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0765","doi-asserted-by":"crossref","first-page":"E67","DOI":"10.12788\/j.sder.2019.010","article-title":"Systemic therapy for advanced cutaneous squamous cell carcinoma","volume":"38","author":"Fitzgerald","year":"2019","journal-title":"Semin. Cutan. Med. Surg."},{"key":"10.1016\/j.bbcan.2025.189461_bb0770","series-title":"Medical Genetics Summaries [Internet]","article-title":"Panitumumab therapy and RAS and BRAF genotype","author":"Dean","year":"2012"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189461_bb0775","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1634\/theoncologist.2011-0461","article-title":"Lapatinib for advanced or metastatic breast cancer","volume":"17","author":"Opdam","year":"2012","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189461_bb0780","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254205","article-title":"Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer","volume":"16","author":"McCorkle","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189461_bb0785","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted Pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189461_bb0790","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3816\/CLC.2010.n.030","article-title":"Src inhibitors in lung cancer: current status and future directions","volume":"11","author":"Rothschild","year":"2010","journal-title":"Clin. Lung Cancer."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189461_bb0795","volume":"14","year":"2025","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0805","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/cancers14010087","article-title":"FDA-approved drugs for hematological malignancies-the last decade review","volume":"14","author":"Sochacka-\u0106wik\u0142a","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189461_bb0810","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/j.sjbs.2021.11.068","article-title":"Protective effect of Bosutinib with caspase inhibitors on human K562 cells","volume":"29","author":"Baty","year":"2022","journal-title":"Saudi J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189461_bb0815","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5045\/br.2021.2021117","article-title":"A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities","volume":"56","author":"Nekoukar","year":"2021","journal-title":"Blood Res."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189461_bb0820","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.bcp.2010.03.034","article-title":"Molecularly targeted therapy in hepatocellular carcinoma","volume":"80","author":"Huynh","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189461_bb0825","doi-asserted-by":"crossref","first-page":"866014","DOI":"10.3389\/fonc.2022.866014","article-title":"IL-6\/JAK\/STAT3 signaling in breast cancer metastasis: biology and treatment","volume":"12","author":"Manore","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189461_bb0830","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1471-2407-12-164","article-title":"Indirubin derivative E804 inhibits angiogenesis","volume":"12","author":"Shin","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2025.189461_bb0835","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2018.02.040","article-title":"Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo","volume":"424","author":"Zhang","year":"2018","journal-title":"Cancer Lett."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189461_bib971","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0840","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1593\/neo.91192","article-title":"INCB16562, a JAK1\/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support","volume":"12","author":"Li","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2025.189461_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105169","article-title":"Natural STAT3 inhibitors: a mini perspective","volume":"115","author":"Wang","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189461_bb0850","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/cells9061451","article-title":"Targeting the JAK\/STAT signaling pathway using phytocompounds for cancer prevention and therapy","volume":"9","author":"Bose","year":"2020","journal-title":"Cells"},{"issue":"14","key":"10.1016\/j.bbcan.2025.189461_bb0855","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/pros.23885","article-title":"The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors","volume":"79","author":"Hellsten","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.bbcan.2025.189461_bb0860","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s42995-022-00162-x","article-title":"Identification of marine natural product Pretrichodermamide B as a STAT3 inhibitor for efficient anticancer therapy","volume":"5","author":"Li","year":"2023","journal-title":"Mar Life Sci Technol"},{"key":"10.1016\/j.bbcan.2025.189461_bb0865","doi-asserted-by":"crossref","first-page":"7838583","DOI":"10.1155\/2022\/7838583","article-title":"The role of natural products as inhibitors of JAK\/STAT signaling pathways in glioblastoma treatment","volume":"2022","author":"Fahmideh","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189461_bb0870","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/biomedicines9030297","article-title":"Antitumor effects of ursolic acid through mediating the inhibition of STAT3\/PD-L1 signaling in non-small cell lung cancer cells","volume":"9","author":"Kang","year":"2021","journal-title":"Biomedicines"},{"issue":"16","key":"10.1016\/j.bbcan.2025.189461_bb0875","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3748\/wjg.v22.i16.4149","article-title":"Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro","volume":"22","author":"Zhu","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189461_bb0880","doi-asserted-by":"crossref","first-page":"965","DOI":"10.7150\/ijms.70733","article-title":"Oridonin represses epithelial-mesenchymal transition and angiogenesis of thyroid cancer via downregulating JAK2\/STAT3 signaling","volume":"19","author":"Liu","year":"2022","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0885","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbrc.2012.08.133","article-title":"Withaferin A inhibits JAK\/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells","volume":"427","author":"Um","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0890","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1038\/s41467-025-61112-6","article-title":"Small-molecule-induced liquid-liquid phase separation suppresses the carcinogenesis of \u03b2-catenin","volume":"16","author":"Yan","year":"2025","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189461_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.110447","article-title":"Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: an updated review (from 2022 to 2024)","volume":"36","author":"Kang","year":"2025","journal-title":"Chin. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189461_bb0900","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/1535-7163.MCT-20-0599","article-title":"Targeting STAT3 with proteolysis targeting chimeras (PROTACs) and next generation antisense oligonucleotides","volume":"20","author":"Shiah","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0905","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054565","article-title":"Stat3 inhibitor stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma","volume":"8","author":"Pan","year":"2013","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.bbcan.2025.189461_bb0910","doi-asserted-by":"crossref","first-page":"15969","DOI":"10.1074\/jbc.M114.564252","article-title":"Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells","volume":"289","author":"Don-Doncow","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189461_bb0920","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3390\/biomedicines10092055","article-title":"Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics","volume":"10","author":"Bhalani","year":"2022","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189461_bb0925","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3390\/biom12091257","article-title":"Recent advances of degradation technologies based on PROTAC mechanism","volume":"12","author":"Xiao","year":"2022","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189461_bb0930","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1042\/BJ20130481","article-title":"Flavanoids induce expression of the suppressor of cytokine signalling 3 (SOCS3) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells","volume":"454","author":"Wiejak","year":"2013","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0935","first-page":"3","article-title":"Implantable immune stents: a new opportunity for cancer treatment","volume":"4","author":"Chen","year":"2023","journal-title":"Biomater. Transl."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189461_bb0940","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.bbcan.2025.189461_bb0945","doi-asserted-by":"crossref","first-page":"20495","DOI":"10.1021\/acs.jmedchem.4c01946","article-title":"Discovery of SD-436: a potent, highly selective and efficacious STAT3 PROTAC degrader capable of achieving complete and long-lasting tumor regression","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189461_bb0950","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.36922\/or.8571","article-title":"Patient-derived tumor organoids-guided adjuvant chemotherapy after surgical resection of intrahepatic cholangiocarcinoma: a multicenter and retrospective study","volume":"1","author":"Zhang","year":"2025","journal-title":"Organ. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189461_bb0955","doi-asserted-by":"crossref","first-page":"025050008","DOI":"10.36922\/OR025050008","article-title":"Application of cancer organoids: the forefront of personalized oncology and preclinical testing","volume":"1","author":"Cao","year":"2025","journal-title":"Organ. Res."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189461_bb0960","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood.2023021423","article-title":"Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia\/lymphoma","volume":"143","author":"Chiba","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189461_bb0965","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3390\/ph16091259","article-title":"Revolutionizing medicinal chemistry: the application of artificial intelligence (AI) in early drug discovery","volume":"16","author":"Han","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189461_bb0970","first-page":"144","article-title":"\u201cYin-Yang philosophy\u201d for the design of anticancer drug delivery nanoparticles","volume":"5","author":"Ai","year":"2024","journal-title":"Biomater. Transl."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25002033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25002033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:36:21Z","timestamp":1781066181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25002033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":185,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0304419X25002033"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189461","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189461"}}